Explore the latest news from Khondrion and its team.
Khondrion highlights potential role of inflammatory lipid modulator prostaglandin E2 in COVID-19 disease and proposes potential...
NIJMEGEN, the Netherlands – Wednesday February 5th, 2020: Khondrion, a clinical-stage pharmaceutical company discovering and developing therapies...
Study will examine impact on cognitive function from one of the most advanced disease-modifying drug treatments for mitochondrial disease in...
Khondrion becomes partner in DuSRA-VOILA collaboration
On Friday 10th January 2020, CEO Jan Smeitink participated in the Annual MitoAction Town Hall Meeting alongside other companies and organisations,...
Khondrion, a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces...
Reflections on SSIEM annual symposium 2019 – Building Bridges Chief Executive Officer of Khondrion, Prof. Dr. Jan Smeitink, reflects on the...
In November 2018, Jan Smeitink, founder and CEO of Khondrion attended the 24th Annual BIO-Europe conference in Copenhagen, Denmark. He spoke to Mike...
Khondrion, the clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease, starts 2019 with the...
In July 2018 Khondrion was awarded €2.3M funding from the EU Horizon 2020 Research and Innovation programme to progress clinical development of KH176, its lead pipeline asset. Prof. Dr. Jan Smeitink, Chief Executive Officer of Khondrion, talks to Catalyze®, who collaborated with Khondrion on the company’s successful funding submission, about his ambitions for Khondrion and the mitochondrial disease research his team is leading.
Khondrion, a leading clinical-stage pharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, today announced the publication of a scientific article reporting on the development and unique mode of action of KH176, a clinical-stage drug candidate for the treatment of mitochondrial diseases.
Khondrion presents Phase II KHENERGY trial data. Data supporting Phase III development of KH176 in mitochondrial disease.
